Foundation Medicine
Foundation Medicine, Natera Launch Early Access for Clinical Personalized ctDNA Monitoring Test
Premium
The personalized and targeted tumor assay, also available for research use in clinical trials, provides a surrogate measure of tumor burden from blood samples.
Foundation Medicine, Boehringer Ingelheim Collaborate on CDx for Biliary Tract Cancer Drug
The companies will develop the FoundationOne CDx test as a companion diagnostic for Boehringer Ingelheim's BI 907828 in the US, Japan, and EU.
Foundation Medicine, Karyopharm Therapeutics Partnering on Endometrial Cancer CDx
The test would help identify patients who have advanced or recurrent TP53 wild-type endometrial cancer and could benefit from the experimental drug Xpovio.
FDA Approves Foundation Medicine Blood Test as CDx for Rozlytrek
FoundationOne Liquid CDx, a liquid biopsy test, is the only blood-based CDx approved for the targeted cancer therapy.
FDA Approves Foundation Medicine Assay as CDx for Certain NSCLC Therapies
The FoundationOne Liquid CDx test can be used with Tarceva (erlotinib), Tagrisso (osimertinib), and Iressa (gefitinib), and other TKIs approved in the future.